

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

CAS-1

RRID:CVCL_1117

Type: Cell Line

Proper Citation

RRID:CVCL_1117

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1117

Proper Citation: RRID:CVCL_1117

Description: Cell line CAS-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: [PMID:12635657](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CAS-1

Synonyms: CAS1

Cross References: CLO:CLO_0002200, CLDB:cl4963, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:589, BioSample:SAMN10987869, cancercellines:CVCL_1117, Cell_Model_Passport:SIDM00212, ChEMBL-Cells:ChEMBL3308187, ChEMBL-Targets:ChEMBL2366100, Cosmic:910943, Cosmic:2367510, Cosmic:2516014, Cosmic-CLP:910943, DepMap:ACH-000464, EGA:EGAS00001000978, GDSC:910943, GEO:GSM886922, GEO:GSM887988, GEO:GSM1669666, IARC_TP53:21216,

ICLC:HTL97009, LiGeA:CCLE_412, LINCS_LDP:LCL-1369,
Pharmacodb:CAS1_187_2019, PRIDE:PXD030304, Progenetix:CVCL_1117,
PubChem_Cell_line:CVCL_1117, Wikidata:Q54808612

ID: CVCL_1117

Record Creation Time: 20220427T215441+0000

Record Last Update: 20260829T231750+0000

Ratings and Alerts

No rating or validation information has been found for CAS-1.

No alerts have been found for CAS-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kolodziejczak AS, et al. (2026) Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma. iScience, 29(2), 114564.

Feng Y, et al. (2023) Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. Cell reports, 42(12), 113503.